慢性靜脈阻塞治療市場、機會、成長動力、產業趨勢分析與預測，2024-2032

Chronic Venous Occlusions Treatment Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

出版日期: 2024年08月20日 | 出版商:

Global Market Insights Inc. | 英文 110 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2023 年，全球慢性靜脈阻塞治療市場價值為 66 億美元，預計 2024-2032 年複合年成長率為 5.0%。市場是由意識增強和技術進步所推動的。慢性靜脈功能不全（CVI）和深部靜脈栓塞（DVT）等慢性靜脈疾病的盛行率不斷上升，增加了有效治療的需求。靜脈注射雷射治療 (EVLT) 和射頻消融 (RFA) 等微創手術由於恢復時間更快、風險更低而越來越受歡迎。雙功超音波等先進影像技術提高了診斷準確性和治療計劃。個人化醫療正在推動客製化療法的發展，提高治療效果和病患照護。

整個慢性靜脈阻塞治療產業根據產品、應用、最終用途和地區進行分類。

該市場分為設備和藥品，預計到 2032 年，藥品市場將超過 51 億美元。抗生素是治療 CVI 引起的潰瘍和皮膚感染的首選藥物。直介面服抗凝血劑 (DOAC) 的興起提高了安全性和便利性，推動了其採用。支持藥物報銷和取得的政府和醫療保健政策進一步促進了市場成長。研發投資的增加正在加速新藥的推出並解決未滿足的醫療需求。

市場也按應用細分，包括深部靜脈栓塞、水腫、靜脈瘀血性潰瘍、靜脈曲張等應用。到 2032 年，水腫領域預計將超過 29 億美元。導致水腫的心臟衰竭、腎臟疾病和靜脈功能不全等疾病的普遍存在，增加了對有效治療的需求。利尿劑和抗發炎藥物等藥物治療的進步正在改善管理和治療結果。人口老化和創新藥物配方正在推動細分市場的擴張。

2023年，北美慢性靜脈閉塞治療市場收入達27億美元，預計將強勁成長。慢性靜脈疾病的高盛行率、先進的醫療基礎設施和微創手術是關鍵促進因素。政府透過有利的報銷政策和醫療保險覆蓋範圍提供的支持正在擴大獲得先進治療的機會。持續的研發投資正在促進創新和新療法的推出，以鞏固北美作為市場領導者的地位。

產業生態系統分析
產業影響力
- 成長動力
  - 靜脈曲張盛行率不斷增加，人們對其治療的認知不斷提高
  - 人們越來越偏好微創手術
  - 骨科手術數量增加
  - 慢性靜脈功能不全治療的技術進步
- 產業陷阱與挑戰
  - 不同治療模式相關的副作用與風險
  - 嚴格的監管指引
成長潛力分析
監管環境
報銷場景
治療景觀
未來市場趨勢
技術景觀
流行病學情景
波特的分析
PESTEL分析
差距分析

第 4 章：競爭格局

介紹
公司矩陣分析
公司市佔率分析
競爭定位矩陣
戰略儀表板

第 5 章：市場估計與預測：按產品分類，2021 - 2032 年

主要趨勢
裝置
- 壓縮裝置
- 靜脈內消融
  - 雷射燒蝕
  - 射頻消融術
- 硬化療法
- 靜脈剝離器
- 其他設備
藥品
- 止痛藥
- 抗生素
- 抗凝血劑
- 其他藥品

第 6 章：市場估計與預測：按應用分類，2021 - 2032

主要趨勢
靜脈曲張
靜脈淤滯性潰瘍
浮腫
深層靜脈栓塞
其他應用

第 7 章：市場估計與預測：按最終用途，2021 - 2032 年

主要趨勢
醫院
門診手術中心
其他最終用戶

第 8 章：市場估計與預測：按地區分類，2021 - 2032 年

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 義大利
- 西班牙
- 荷蘭
- 歐洲其他地區
亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區

第 9 章：公司簡介

3M Company
Bayer AG
Boston Scientific Corporation
Candela
ConvaTec Inc.
Fotona
Julius Zorn GmbH
Leucadia Pharmaceuticals (Hikma)
Medi GmbH and Co. KG
Medtronic plc
Merz Pharma
Pfizer Inc.
Sanofi
Sciton, Inc
Tactile Medical
Venclose, Inc. (Becton Dickinson and Company)
Viatris Inc.

簡介目錄

Product Code: 5398

The Global Chronic Venous Occlusions Treatment Market was valued at USD 6.6 billion in 2023 and is projected to grow at a CAGR of 5.0% from 2024-2032. The market is driven by increased awareness and technological advancements. The rising prevalence of chronic venous diseases like chronic venous insufficiency (CVI) and deep vein thrombosis (DVT) is boosting demand for effective treatments. Minimally invasive procedures, such as endovenous laser therapy (EVLT) and radiofrequency ablation (RFA), are gaining popularity due to faster recovery times and lower risks. Advanced imaging technologies like duplex ultrasound have improved diagnostic accuracy and treatment planning. Personalized medicine is driving the development of tailored therapies, enhancing treatment efficacy and patient care.

The overall chronic venous occlusions treatment industry is classified based on the product, application, end use , and region.

The market is segmented into devices and drugs, with the drugs segment projected to surpass USD 5.1 billion by 2032. Various drugs, including analgesics, antibiotics, and anticoagulants, are used in diagnosis and therapy. Antibiotics are preferred for treating ulcers and skin infections from CVI. The rise of direct oral anticoagulants (DOACs) offers improved safety and convenience, driving their adoption. Government and healthcare policies supporting drug reimbursement and access are further bolstering market growth. Increased R&D investments are accelerating the introduction of new drugs and addressing unmet medical needs.

The market is also segmented by application, including deep vein thrombosis, edema, venous stasis ulcers, varicose veins, and other applications. The edema segment is expected to exceed USD 2.9 billion by 2032. The prevalence of conditions like heart failure, kidney disease, and venous insufficiency, which lead to edema, is increasing demand for effective treatments. Advances in pharmacological therapies, such as diuretics and anti-inflammatory drugs, are improving management and treatment outcomes. The aging population and innovative drug formulations are driving segment expansion.

In 2023, North America accounted for USD 2.7 billion in revenue from the chronic venous occlusion's treatment market, with robust growth projected. The high prevalence of chronic venous diseases, advanced healthcare infrastructure, and minimally invasive procedures are key drivers. Government support through favorable reimbursement policies and health insurance coverage is broadening access to advanced treatments. Ongoing R&D investments are fostering innovation and the introduction of new therapies, solidifying North America's position as a market leader.

Chapter 1 Methodology and Scope

1.1 Market scope and definition
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing prevalence of varicose veins coupled with rising awareness regarding its treatment
  - 3.2.1.2 Growing preference for minimally invasive procedures
  - 3.2.1.3 Rise in number of orthopedic procedures
  - 3.2.1.4 Technological advancements pertaining to chronic venous insufficiency treatment therapies
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 Side effects and risks associated with different treatment modes
  - 3.2.2.2 Strict regulatory guidelines
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Reimbursement scenario
3.6 Treatment landscape
3.7 Future market trends
3.8 Technological landscape
3.9 Epidemiology scenario
3.10 Porter's analysis
3.11 PESTEL analysis
3.12 Gap analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Company market share analysis
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Devices
- 5.2.1 Compression devices
- 5.2.2 Endovenous ablation
  - 5.2.2.1 Laser ablation
  - 5.2.2.2 Radiofrequency ablation
- 5.2.3 Sclerotherapy
- 5.2.4 Vein stripper
- 5.2.5 Other devices
5.3 Drugs
- 5.3.1 Analgesics
- 5.3.2 Antibiotics
- 5.3.3 Anticoagulants
- 5.3.4 Other drugs

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Varicose veins
6.3 Venous stasis ulcers
6.4 Edema
6.5 Deep vein thrombosis
6.6 Other applications

Chapter 7 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Hospitals
7.3 Ambulatory surgical centers
7.4 Other end-users

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Italy
- 8.3.5 Spain
- 8.3.6 Netherlands
- 8.3.7 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
- 8.5.4 Rest of Latin America
8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE
- 8.6.4 Rest of Middle East and Africa